Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | USP8 | P40818 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784497 | 0.90 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3777973 | 0.88 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3376873 | 0.84 | P2RX7 (0.42) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL13068788 | 0.83 | MEN1 (0.41) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL1970190 | 0.80 | SCN9A (0.40) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3376875 | 0.80 | MEN1 (0.42) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3786565 | 0.78 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3779306 | 0.78 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3779313 | 0.78 | ALDH1A1 (0.46) | MEN1KMT2AP2RY1USP2USP8 | |
| SCHEMBL3787111 | 0.78 | ALDH1A1 (0.44) | MEN1KMT2AP2RY1USP2USP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | MEN1 4653/4885KMT2A 3139/4885P2RY1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.